Heart shield: common diabetes drug may prevent Chemo-Induced heart damage

NCT ID NCT07070765

First seen May 13, 2026 · Last updated May 15, 2026 · Updated 1 time

Summary

This study tests whether taking dapagliflozin (a drug used for diabetes) daily during chemotherapy can reduce heart damage in breast cancer patients. About 70 women with low to medium heart risk will take the drug while receiving anthracycline chemotherapy. The goal is to see if the drug helps keep the heart's energy levels healthy and prevents long-term heart problems.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Cardiac Research Office, Aberdeen Royal Infirmary

    RECRUITING

    Aberdeen, Aberdeenshire, AB25 2ZD, United Kingdom

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • University of Aberdeen

    RECRUITING

    Aberdeen, AB25 2ZD, United Kingdom

    Contact Email: •••••@•••••

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.